The first batch of test material from the large-scale production of Nanologica AB’s silica has been approved. The quality of the material produced at the CMO Sterling Pharma Solutions in the UK is identical to the material produced at Nanologica’s plant in Södertälje.
In December 2020, the first batch of test material from the upscaling to large-scale production of Nanologica’s silica was delivered. Rigorous quality testing of the silica now confirms identical quality to the silica produced at the site in Södertälje.
” We are very excited and pleased to have confirmed a successful upscaling of production. The quality of the product is excellent, which means that all results generated in Södertälje and with customers are applicable for products manufactured at large scale. It is with great confidence we now accelerate production of silica at ton scale”, says Andreas Bhagwani, CEO Nanologica.
Upscaling to large-scale production of Nanologica’s silica started in July 2019. The silica is produced according to Nanologica’s proprietary methods at the contract manufacturer Sterling Pharma Solutions in the UK. In the later part of 2021, after production trimming, silica product is expected to be delivered from the facilities at Sterling.
For further information, please contact:
Johanna Johansson, IR Nanologica
Ph: +46 72 211 21 90 or e-mail: email@example.com
About Nanologica AB (publ)
Nanologica was founded in 2004 and is a nanotechnology company developing nanoporous silica particles for applications within life science. Nanologica is world-leading in controlling the shape, size, and type of porosity of silica particles. This knowledge is applied within drug development and chromatography (a separation technique used in drug development and drug production). The company’s mission is to contribute to better and cheaper treatments for patients worldwide through the technology platform NLAB Silica™. Nanologica’s stock (NICA) is listed on Spotlight Stock Market. For further information, please visit www.nanologica.com.